Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company that leverages artificial intelligence and machine learning, has announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. The event, led by President and CEO Panna Sharma and other management members, will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company's RADR(R) and Open-Medicine AI platforms.
The announcement comes at a pivotal time for the company as it continues to integrate AI across its operations, from drug discovery to clinical development. Lantern's proprietary RADR(R) platform is designed to identify biomarkers and patient populations most likely to respond to its pipeline of cancer therapies, potentially increasing the efficiency and success rate of clinical trials. Meanwhile, the Open-Medicine AI platform, through its commercial availability of withZeta.ai, represents a new revenue stream for the company, offering a subscription-based research tool for the global biomedical and drug development community.
Lantern's clinical pipeline includes LP-184 (acylfulvene), a compound being developed for multiple solid tumors, and LP-284, a TC-NER targeting compound for hematologic and solid tumors. The company is also evaluating LP-300 in the HARMONIC Phase 2 trial, which targets never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. These programs highlight the company's broad approach to addressing high-unmet medical needs in oncology.
The webcast will likely offer insights into the progress of these trials and the adoption of withZeta.ai, which could be key drivers of the company's valuation. For investors, the update may provide clarity on the timeline for data readouts and the potential commercialization of its AI platforms. According to the press release, a webcast replay will be available through the investor relations section of Lantern Pharma's website following the event. The full press release can be accessed at https://ibn.fm/l80kv.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's recent strategic moves, including the commercial launch of withZeta.ai, signal a transformation from a pure-play drug developer to an AI-driven entity that could also generate recurring revenue from its technology. This dual focus may appeal to investors seeking exposure to both the high-risk, high-reward nature of oncology drug development and the more predictable economics of software-as-a-service models in the biotech space.
As the company prepares to report its second-quarter results, stakeholders will be watching for updates on enrollment in the HARMONIC trial, any new data from LP-184 studies, and the traction of withZeta.ai in the market. The webcast could also address the company's cash runway and funding needs, given the capital-intensive nature of clinical trials. With AI playing an increasingly central role in drug discovery, Lantern's progress may offer a bellwether for how AI-driven approaches can reshape oncology development. For more information on Lantern Pharma, visit its newsroom at https://ibn.fm/LTRN.
